Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-1)

Sum=24

Sep 14, 2024 (publication date) through Sep 10, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Sep 14, 2024; 30(34): 3862-3867
Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3862

Table 1 Epidemiological studies on associations of glucagon-like peptide-1 receptor agonist and risk of cholangiocarcinoma

Ref.	Region of study	Study design	Results (95%CI)
Abrahami et al[26], 2018	United Kingdom	Cohort study	HR: 1.97 (0.83-4.66)
Giorda et al[28], 2020	Italy	Case-control study	OR: 1.09 (0.63-1.89)
Ueda et al[27], 2021	Scandinavia	Cohort study	HR: 1.25 (0.89-1.76)
He et al[29], 2022	Worldwide	Systematic review and meta-analysis	RR: 1.43 (0.80-2.56)

HR: Hazard ratio; OR: Odds ratio; RR: Risk ratio.

Citation: Trakoonsenathong R, Chiu CF, Saengboonmee C. Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma. World J Gastroenterol 2024; 30(34): 3862-3867
URL: https://www.wjgnet.com/1007-9327/full/v30/i34/3862.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i34.3862